By inhibiting the binding of CXCL8 and CXCR1/2, the aggregation of immunosuppressive cells (e.g., neutrophils, TAMs, etc.)in the TME can be reduced, thereby promoting the anti-tumor activity of effector T cells (392, 393). The gene discussed is CXCR1; the disease is neoplasm.